查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601188

藥品製造市場：依配方、藥物開發類型、給藥途徑、藥物、年齡層、通路、治療領域 - 2025-2030 年全球預測

Pharmaceutical Manufacturing Market by Formulation (Capsules, Injectable, Powders), Drug Development Type (In-House, Outsource), Route of Administration, Drugs, Age Group, Distribution Channel, Therapy Area - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年藥品製造市場價值為6,206.8億美元，預計2024年將達到6,724.4億美元，複合年成長率為8.66%，到2030年將達到11.1017億美元。

藥品製造部門涵蓋藥品和醫療療法的生產、開發和商業化，重點在於藥品生產的品質、效率和安全性。全球健康需求不斷成長、慢性病盛行率不斷上升以及對創新治療的持續需求推動了對該領域的需求。其應用範圍包括 A​​PI（活性藥物成分）的生產、最終劑型的配製以及生物技術的進步。最終用途包括醫院、診所、研究機構、零售藥局等。影響該市場的關鍵成長要素包括自動化和人工智慧整合等技術進步、研發投資的增加以及政府的支援措施。此外，個人化醫療和生技藥品的成長趨勢帶來了巨大的成長機會。公司可以透過投資生技研發、提高產能以及採用永續實踐來減少對環境的影響，從而利用這些趨勢。

主要市場統計
基準年[2023] 6206.8億美元
預測年份 [2024] 6724.4億美元
預測年份 [2030] 11,101.70億美元
複合年成長率（%） 8.66%

然而，市場面臨一些限制和挑戰，包括嚴格的監管要求、高昂的藥物開發成本以及與生物技術整合相關的複雜性。全球大流行也凸顯了供應鏈的脆弱性，並強化了對更具彈性系統的需求。鼓勵市場相關人員探索創新領域，例如數位健康工具、先進的藥物輸送系統以及利用巨量資料分析來最佳化製造流程。此外，由於醫療保健支出的增加，新興國家提供了市場擴張機會。市場競爭激烈，創新壓力持續存在，需要靈活的策略來維持市場佔有率。公司應注重合作夥伴關係、開放式創新和策略性收購，以推動成長並克服現有障礙。整體而言，市場格局的特點是由科學創新和監管環境驅動的動態性，相關人員必須保持積極主動的策略方法，才能在這個充滿挑戰的環境中取得成功。

市場動態：揭示快速發展的藥品製造市場的關鍵市場洞察

供需的動態交互作用正在改變藥品製造市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球對疫苗和藥物的需求增加
    • 醫藥品研究開發費用增加
    • 老年人口增加和慢性病發生率增加
  • 市場限制因素
    • 與藥品製造相關的高成本和複雜性
  • 市場機會
    • 增加藥品製造領域的投資和融資計劃
    • 新藥品製造技術的出現
  • 市場問題
    • 政府對製藥公司的嚴格監管

波特五力：駕馭藥品製造市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解藥品製造市場的外部影響

外部宏觀環境因素在塑造藥品製造市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解藥品製造市場的競爭格局

對藥品製造市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：藥品製造市場供應商績效評估

FPNV定位矩陣是評估藥品製造市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

該報告提供了涵蓋關鍵焦點細分市場的全面市場分析。

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球對疫苗和藥物的需求增加
      • 醫藥品研究開發費用增加
      • 老年人口增加和慢性病發生率增加
    • 抑制因素
      • 與藥品製造相關的高成本和複雜性
    • 機會
      • 加大醫藥製造領域投資金籌措力度
      • 新藥品製造技術的出現
    • 任務
      • 政府對製藥公司的嚴格監管
  • 市場區隔分析
    • 配方：投資激增以支持注射劑的強勁研發
    • 藥物開發類型：由於成本效益，外包藥物生產的使用增加
    • 給藥途徑：隨著慢性病盛行率的不斷增加，腸外給藥的研發活動不斷增加。
    • 藥品：非處方藥 (OTC) 的趨勢
    • 年齡層：非常需要藥物組合來治療老年人的疾病
    • 分銷通路：藥品非零售通路的滲透
    • 治療領域：開發新腫瘤治療方法的創新浪潮
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境
  • 客戶客製化
    • 2022 年最暢銷組合藥物和非處方藥列表

第6章 藥品製造市場：依配方分類

  • 介紹
  • 膠囊
  • 注射
  • 粉末
  • 噴
  • 暫停
  • 錠劑

第7章藥品製造市場：依藥物開發類型

  • 介紹
  • 公司內部
  • 外包

第8章 藥品製造市場：依管理途徑分類

  • 介紹
  • 吸入
  • 口服
  • 胃腸外的
  • 局部的

第9章藥品製造市場：依藥品分類

  • 介紹
  • 非處方藥 (OTC)
  • 聯合用藥

第10章藥品製造市場：依年齡層別

  • 介紹
  • 成人
  • 嬰兒和青少年
  • 老年人

第11章藥品製造市場：依通路分類

  • 介紹
  • 非零售
  • 零售

第12章藥品製造市場：依治療領域

  • 介紹
  • 過敏
  • 心血管疾病
  • 皮膚科
  • 糖尿病
  • 胃腸病學
  • 感染疾病
  • 神經病學
  • 腫瘤學
  • 眼科
  • 疼痛管理
  • 心理保健
  • 肺
  • 腎臟疾病
  • 呼吸系統疾病

第13章美洲藥品製造市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太藥品製造市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章歐洲、中東和非洲的藥品製造市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 印度製藥業提案投資1500億盧比
    • Glenmark Pharma 在印度推出特力利汀 +Dapagliflozin+Metformin的 FDC 三重療法，用於治療第 2 型糖尿病
    • Novo 和 Torrent 擴大合作夥伴關係的可能性
    • 美國FDA核准百時美施貴寶的 Reblozyl (luspatercept-aamt) 作為第一線治療可能需要輸血的低危險骨髓發育不良症候群(MDS) 成人貧血患者
    • 芬蘭製造廠將擴建 5,000 萬歐元
    • Aenova 與 Galvita 結成策略聯盟
    • 諾和諾德投資 21 億歐元擴建 Hillerod製造地
    • 禮來公司 (Eli Lilly) 在印第安納州的製造業支出計畫中增加了 16 億美元
    • FDA核准Pluvict 在美國諾華米爾本工廠商業化生產
    • 武田投資 1000 億日圓在日本新血漿分餾產品生產設施
    • 輝瑞收購 Abzena 的生技藥品生產設施

公司名單

  • AstraZeneca PLC
  • Lupin Limited
  • Piramal Pharma Limited
  • Asymchem, Inc.
  • Recipharm AB
  • Biocon Limited
  • AbbVie Inc.
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Merck KGaA
  • Amgen Inc.
  • Advent Pharma Ltd.
  • Johnson & Johnson Services, Inc.
  • Azurity Pharmaceuticals, Inc.
  • Famar Group
  • Zeon Lifesciences Ltd.
  • Actiza Pharmaceutical Pvt. Ltd.
  • Cipla Limited
  • Aenova Group GmbH
  • Boehringer Ingelheim International GmbH
  • Moderna, Inc.
  • Thermo Fisher Scientific Inc.
  • Sun Pharmaceutical Industries Ltd.
  • BioNTech SE
  • Lonza Group AG
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Emcure Pharmaceuticals Limited
  • Veranova, LP
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Sanofi SA
  • Novo Nordisk A/S
  • Glenmark Pharmaceuticals Ltd.
  • Abbott Laboratories
  • GlaxoSmithKline PLC
  • McKesson Corporation
Product Code: MRR-22146147675F

The Pharmaceutical Manufacturing Market was valued at USD 620.68 billion in 2023, expected to reach USD 672.44 billion in 2024, and is projected to grow at a CAGR of 8.66%, to USD 1,110.17 billion by 2030.

The pharmaceutical manufacturing sector encompasses the production, development, and commercialization of drugs and medical therapies, with a focus on quality, efficiency, and safety in the production of medicinal products. The necessity of this sector is underpinned by the growing global health demands, increasing prevalence of chronic diseases, and the continuous need for innovative therapeutics. Its applications span across the production of APIs (Active Pharmaceutical Ingredients), formulation of finished dosage forms, and advancements in biotechnology. The end-use scope includes hospitals, clinics, research institutes, and retail pharmacies. Key growth factors influencing this market include technological advancements such as automation and AI integration, growing R&D investments, and supportive government policies. Additionally, the rising trend towards personalized medicine and biologics offers significant growth opportunities. Companies can capitalize on these trends by investing in biotech R&D, enhancing their production capabilities, and adopting sustainable practices to reduce environmental impact.

KEY MARKET STATISTICS
Base Year [2023] USD 620.68 billion
Estimated Year [2024] USD 672.44 billion
Forecast Year [2030] USD 1,110.17 billion
CAGR (%) 8.66%

However, the market faces several limitations and challenges, such as stringent regulatory requirements, high costs of drug development, and the complexities involved in biotechnology integration. The global pandemic has also highlighted vulnerabilities in supply chains, reinforcing the need for more resilient systems. Market players are encouraged to explore areas of innovation like digital health tools, advanced drug delivery systems, and the use of big data analytics for optimizing manufacturing processes. Additionally, developing countries present opportunities for market expansion due to increasing healthcare expenditure. The market is highly competitive, with continuous pressure to innovate, demanding agile strategies to maintain market share. Companies should focus on collaborative partnerships, open innovation, and strategic acquisitions to drive growth and overcome existing barriers. Overall, the pharmaceutical manufacturing market is characterized by its dynamic nature, driven by both scientific innovation and regulatory landscapes, thus requiring stakeholders to maintain a proactive and strategic approach to navigate and thrive in this challenging environment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmaceutical Manufacturing Market

The Pharmaceutical Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in global demand for vaccines and drugs
    • Growing pharmaceutical R&D spending
    • Growth in geriatric population and incidence rate of chronic disorders
  • Market Restraints
    • High costs and complexities associated with the pharma production
  • Market Opportunities
    • Rise in the investment and funding programs in the pharmaceutical manufacturing sector
    • Emergence of novel pharmaceutical manufacturing technologies
  • Market Challenges
    • Stringent government regulations for pharmaceutical companies

Porter's Five Forces: A Strategic Tool for Navigating the Pharmaceutical Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmaceutical Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmaceutical Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmaceutical Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmaceutical Manufacturing Market

A detailed market share analysis in the Pharmaceutical Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmaceutical Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmaceutical Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Lupin Limited, Piramal Pharma Limited, Asymchem, Inc., Recipharm AB, Biocon Limited, AbbVie Inc., Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Pfizer, Inc., Merck KGaA, Amgen Inc., Advent Pharma Ltd., Johnson & Johnson Services, Inc., Azurity Pharmaceuticals, Inc., Famar Group, Zeon Lifesciences Ltd., Actiza Pharmaceutical Pvt. Ltd., Cipla Limited, Aenova Group GmbH, Boehringer Ingelheim International GmbH, Moderna, Inc., Thermo Fisher Scientific Inc., Sun Pharmaceutical Industries Ltd., BioNTech SE, Lonza Group AG, Novartis AG, F. Hoffmann-La Roche Ltd., Emcure Pharmaceuticals Limited, Veranova, L.P., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Sanofi S.A., Novo Nordisk A/S, Glenmark Pharmaceuticals Ltd., Abbott Laboratories, GlaxoSmithKline PLC, and McKesson Corporation.

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Formulation, market is studied across Capsules, Injectable, Powders, Sprays, Suspensions, and Tablets.
  • Based on Drug Development Type, market is studied across In-House and Outsource.
  • Based on Route of Administration, market is studied across Inhalations, Oral, Parenteral, and Topical.
  • Based on Drugs, market is studied across Over-the-Counter (OTC) Medicines and Prescription Medicines.
  • Based on Age Group, market is studied across Adults, Children & Adolescents, and Geriatric.
  • Based on Distribution Channel, market is studied across Non-Retail and Retail.
  • Based on Therapy Area, market is studied across Allergy, Cardiovascular Diseases, Dermatology, Diabetes, Gastroenterology, Infectious Disease, Neurology, Oncology, Ophthalmology, Pain Management, Psychiatry, Pulmonary, Renal Disease, and Respiratory Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in global demand for vaccines and drugs
      • 5.1.1.2. Growing pharmaceutical R&D spending
      • 5.1.1.3. Growth in geriatric population and incidence rate of chronic disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High costs and complexities associated with the pharma production
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in the investment and funding programs in the pharmaceutical manufacturing sector
      • 5.1.3.2. Emergence of novel pharmaceutical manufacturing technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations for pharmaceutical companies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Formulation: Surging investment to support robust research and development of injectable formulations
    • 5.2.2. Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness
    • 5.2.3. Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease
    • 5.2.4. Drugs: Inclination toward Over-the-counter (OTC) drugs
    • 5.2.5. Age Group: Significant need for drug formulations to treat geriatric medical conditions
    • 5.2.6. Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals
    • 5.2.7. Therapy Area: Wave of innovations toward development of new oncology treatment modalities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. List of Top Selling Prescription and Over-the-Counter Drugs in 2022

6. Pharmaceutical Manufacturing Market, by Formulation

  • 6.1. Introduction
  • 6.2. Capsules
  • 6.3. Injectable
  • 6.4. Powders
  • 6.5. Sprays
  • 6.6. Suspensions
  • 6.7. Tablets

7. Pharmaceutical Manufacturing Market, by Drug Development Type

  • 7.1. Introduction
  • 7.2. In-House
  • 7.3. Outsource

8. Pharmaceutical Manufacturing Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Inhalations
  • 8.3. Oral
  • 8.4. Parenteral
  • 8.5. Topical

9. Pharmaceutical Manufacturing Market, by Drugs

  • 9.1. Introduction
  • 9.2. Over-the-Counter (OTC) Medicines
  • 9.3. Prescription Medicines

10. Pharmaceutical Manufacturing Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adults
  • 10.3. Children & Adolescents
  • 10.4. Geriatric

11. Pharmaceutical Manufacturing Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Non-Retail
  • 11.3. Retail

12. Pharmaceutical Manufacturing Market, by Therapy Area

  • 12.1. Introduction
  • 12.2. Allergy
  • 12.3. Cardiovascular Diseases
  • 12.4. Dermatology
  • 12.5. Diabetes
  • 12.6. Gastroenterology
  • 12.7. Infectious Disease
  • 12.8. Neurology
  • 12.9. Oncology
  • 12.10. Ophthalmology
  • 12.11. Pain Management
  • 12.12. Psychiatry
  • 12.13. Pulmonary
  • 12.14. Renal Disease
  • 12.15. Respiratory Diseases

13. Americas Pharmaceutical Manufacturing Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Pharmaceutical Manufacturing Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Pharmaceutical Manufacturing Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. INR 15,000 Crore Proposed in Pharma Sector, India
    • 16.3.2. Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes
    • 16.3.3. Novo, Torrent may Widen Tie-Up
    • 16.3.4. U.S. FDA Approves Bristol Myers Squibb's Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
    • 16.3.5. Finnish Manufacturing Facility to Get EUR 50 Million Expansion
    • 16.3.6. Aenova and Galvita Enter Strategic Partnership
    • 16.3.7. Novo Nordisk Invests EUR 2.1 Billion in Hillerod Manufacturing Expansion
    • 16.3.8. Eli Lilly Adds USD 1.6 Billion to its Manufacturing Spending Plan in Indiana
    • 16.3.9. FDA Approves Novartis Millburn Facility for U.S. Commercial Production of Pluvicto
    • 16.3.10. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
    • 16.3.11. Pfizer Acquires Abzena's Biologic Manufacturing Facility

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Lupin Limited
  • 3. Piramal Pharma Limited
  • 4. Asymchem, Inc.
  • 5. Recipharm AB
  • 6. Biocon Limited
  • 7. AbbVie Inc.
  • 8. Bayer AG
  • 9. Takeda Pharmaceutical Company Limited
  • 10. Eli Lilly and Company
  • 11. Pfizer, Inc.
  • 12. Merck KGaA
  • 13. Amgen Inc.
  • 14. Advent Pharma Ltd.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Azurity Pharmaceuticals, Inc.
  • 17. Famar Group
  • 18. Zeon Lifesciences Ltd.
  • 19. Actiza Pharmaceutical Pvt. Ltd.
  • 20. Cipla Limited
  • 21. Aenova Group GmbH
  • 22. Boehringer Ingelheim International GmbH
  • 23. Moderna, Inc.
  • 24. Thermo Fisher Scientific Inc.
  • 25. Sun Pharmaceutical Industries Ltd.
  • 26. BioNTech SE
  • 27. Lonza Group AG
  • 28. Novartis AG
  • 29. F. Hoffmann-La Roche Ltd.
  • 30. Emcure Pharmaceuticals Limited
  • 31. Veranova, L.P.
  • 32. Bristol-Myers Squibb Company
  • 33. Gilead Sciences, Inc.
  • 34. Sanofi S.A.
  • 35. Novo Nordisk A/S
  • 36. Glenmark Pharmaceuticals Ltd.
  • 37. Abbott Laboratories
  • 38. GlaxoSmithKline PLC
  • 39. McKesson Corporation

LIST OF FIGURES

  • FIGURE 1. PHARMACEUTICAL MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. PHARMACEUTICAL MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. PHARMACEUTICAL MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACEUTICAL MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OUTSOURCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INHALATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PRESCRIPTION MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NON-RETAIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RETAIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PSYCHIATRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PULMONARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RENAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 149. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 155. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 156. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 162. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 163. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 166. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. TAIWAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 169. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 170. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. THAILAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 176. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 177. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. VIETNAM PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 191. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 192. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 195. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 196. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. DENMARK PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 198. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 199. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 202. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 203. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. EGYPT PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 205. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 206. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 210. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. FINLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 212. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 213. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 217. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. FRANCE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 219. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 220. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 224. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. GERMANY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 226. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 227. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. ISRAEL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 233. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 234. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 237. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 238. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. ITALY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 240. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 241. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 244. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 245. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 246. NETHERLANDS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 247. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 248. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 251. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 252. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 253. NIGERIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 254. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 255. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 258. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 259. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. NORWAY PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 261. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 262. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 265. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 266. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. POLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 268. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 269. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 272. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 274. QATAR PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 275. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 276. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 279. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 280. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 281. RUSSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 282. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 283. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 285. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 286. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 287. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 288. SAUDI ARABIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 293. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 294. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 295. SOUTH AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 296. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 297. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 300. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 301. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 302. SPAIN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 303. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 304. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 307. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 308. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 309. SWEDEN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 310. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 311. SWITZERLAND PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. SWITZERLAND PHARMACEU